bioAffinity Technologies, Inc. has reported a significant milestone, announcing that a record number of CyPath® Lung tests were performed in October 2026. This achievement marks the highest monthly testing volume for the company's noninvasive lung cancer test, indicating strong demand and potential growth in their operations.
The announcement is particularly important as it underscores bioAffinity's commitment to advancing noninvasive testing methods in the healthcare industry. With the increasing focus on patient-centered care, the success of CyPath® could position the company favorably against competitors in the commercial physical and biological research sector.
Background
bioAffinity Technologies, Inc. is a Delaware corporation engaged in the development of innovative diagnostic solutions. The company operates under the Standard Industrial Classification (SIC) code 8731, which pertains to Services-Commercial Physical & Biological Research. The firm trades on the Nasdaq under the ticker symbols BIAF and BIAFW.
What the Filing Says
According to the recent SEC filing dated November 17, 2026, the company stated, "On November 11, 2026, bioAffinity Technologies, Inc. announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test." A press release detailing this achievement was included as Exhibit 99.1 in the filing.
Impact
This development is likely to impact various stakeholders, including healthcare providers, patients, and investors. The increase in testing volume could enhance patient access to early lung cancer detection, potentially improving outcomes. For investors, this growth may signal a positive trajectory for bioAffinity's market position and future profitability.
What's Next
The filing does not specify what happens next for bioAffinity Technologies, Inc. However, the company may continue to leverage this momentum to expand its market presence and further develop its product offerings.
Read Next
Purple Biotech Reports Q3 2026 Results, Updates on IM1240
Adagene Launches Phase 1 Trial for Colorectal Cancer Therapy
Netlist Inc. Appoints James Hickey to Board of Directors
Electra Battery Materials Expands Nickel Strategy with Positive
Boynton John Wilson IV sells shares in Nebius Group N.V.
Linkhome Holdings adds two independent directors to board








